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G-protein-coupled receptors serve as key signal transduction conduits, linking extracellular inputs
with diverse cellular responses. These receptors eluded structural characterization for decades
following their identification. A landmark structure of rhodopsin provided a basis for structure-
function studies and homology modeling, but advances in receptor biology suffered from a lack
of receptor-specific structural insights. The recent explosion in GPCR structures confirms some
features predicted by rhodopsin-based models, and more importantly, it reveals unexpected
ligand-binding modes and critical aspects of the receptor activation process. The new structures
also promise to foster studies testing emerging models for GPCR function such as receptor dimer-
ization and ligand-biased signaling.Introduction
G-protein-coupled receptors are seven transmembrane domain
(TM) proteins that are located in theplasmamembrane and trans-
duce signals through their interactions with both extracellular
small-molecule ligands and intracellular G proteins to initiate
signaling cascades that allow cells to respond to changes within
their environment. With more than 800 members in the human
genome, G-protein-coupled receptors (GPCRs) represent the
largest family of proteins involved in signal transduction across
biological membranes. They recognize a large diversity of
hormones and neurotransmitters and, as a consequence, are
major targets for the development of drugs for many clinical indi-
cations. Theyhavebeengrouped in fiveor six classes (depending
on the classification criteria used),withmost of thembelonging to
classes A (rhodopsin-like), B (secretin-like), and C (metabotropic
glutamate-like) that are defined by the conservation of unique
structural features (Foord et al., 2005). GPCRs generally operate
within a transduction unit containing the receptor that binds the
soluble signal, a heterotrimeric (abg) G protein, and an effector
component such as an enzyme or a channel that promotes the
intracellular changes leading to a biological response (Figure 1).
Ligand binding activates GPCRs, which then mediate a nucleo-
tide exchange reaction for the associated Ga subunit. In general,
drugs binding at GPCRs were believed to act exclusively by
promoting this reaction. More recently, the ability of GPCRs to
signal in a G-protein-independent manner through their direct
interactions with other effectors such as b-arrestin has also
emerged (Galandrin et al., 2007).
In the last three decades, numerous cellular, biochemical, and
biophysical studies have provided a general appreciation of how
GPCRs function. However, these studies do not offer a detailed
description of the molecular events linking ligand binding to
receptor activation. Major efforts to obtain high-resolution
GPCR structures were therefore driven by the idea that three-
dimensional crystal structures would provide an atomic narrative14 Cell 151, September 28, 2012 ª2012 Elsevier Inc.of the conformational changes leading to the activation of
G-protein-dependent and -independent signaling, thus yielding
the needed information to understand drug action and support
rational design.
Although GPCRs have been known for more than 40 years,
the first high-resolution structure, that of the visual receptor
rhodopsin, wasn’t solved until 2000 (Palczewski et al., 2000),
and another 7 years were needed for the determination of the
first GPCRs bound to diffusible ligands such as hormones or
neurotransmitters (Cherezov et al., 2007; Rasmussen et al.,
2007; Rosenbaum et al., 2007). The delay in generating crystal
structures of GPCRs other than rhodopsin resulted largely from
methodological difficulties associated with the crystallization
of transmembrane proteins. Recent technological advances in
engineering, producing and purifying membrane proteins, crys-
tal formation, and X-ray diffraction paved the way for the recent
explosion of GPCR structural biology work. In the last 5 years, 47
structures representing 13 distinct GPCRs have been solved—in
many cases with resolution of 3 Ǻ or better (Table 1).
Early Days of Structure and Modeling
Using electron microscopy, Henderson and Unwin (1975) gener-
ated the first three-dimensional structure of a 7TM protein
from diffraction images of Halobacterium halobium bacteriorho-
dopsin, a highly expressed proton pump. Once the cloning of
GPCRs revealed their 7TM topology, the bacteriorhodopsin
structure, as well as the subsequently solved 3D projection
maps of eukaryotic rhodopsin (Schertler et al., 1993), became
templates of choice to model GPCRs (Baldwin et al., 1997; Hen-
derson et al., 1990). Although these models were quite useful in
driving early site-directed mutagenesis studies and for probing
the structure-activity relationship of the receptors, the relatively
low resolution (>9Ǻ) prevented detailed analyses. An important
step forward toward a more precise representation of GPCRs
came with the high-resolution (2.8 Ǻ) structure of the bovine
Figure 1. G-Protein-Coupled Receptor Topological Organization
and Signaling Paradigm
Serpentine illustration of the seven transmembrane topological organization of
GPCRs. The positions of some of the conserved structural features of the class
A GPCRs such as the DRY and NPXXYmotifs, as well as the toggle switch, are
indicated. The dotted line indicates the two domains (in red) involved in the
ionic interactions known as the ionic lock. The figure also illustrates the
canonical G-protein-dependent and more recently described G-protein-
independent signaling modes involving b-arrestin and other signaling effec-
tors. ICL, intracellular loop; ECL, extracellular loop.
Table 1. GPCR Structures
Receptor Ligand
PDB Accession
Number
Inverse Agonists
Adenosine A2A caffeine 3RFM
XAC 3REY
ZM241385 3EML-3PWH-
3VG9-3VGA
b2-adrenergic carazolol 3KJ6-2RH1-
2R4R-2R4S
compound aa 3NY9
ICI-118551 3NY8
timolol 3D4S
Histamine H1 doxepin 3RZE
M2 muscarinic acetylcholine QNB 3UON
M3 muscarinic acetylcholine tiotropium 4DAJ
Antagonists
Adenosine A2A compound b
b 3UZA
compound cc 3UZC
b1-adrenergic carazolol 2YCW
cyanopindolol 2VT4-2YCX-2YCY
iodocyanopindolol 2YCZ
b2-adrenergic alprenolol 3NYA
CXC chemokine type 4 CVX15 3OE0
IT1t 3ODU-3OE6-
3OE8-3OE9
Dopamine D3 eticlopride 3PBL
d opioid naltrindol 4EJ4
k opioid JDTic 4DJH
m opioid b-funaltrexamine 4DKL
Nociceptin/orphanin FQ C-24 4EA3
Sphingosine-1-phosphate
type 1
ML056 3V2W
3V2Y
Agonists
b1-adrenergic carmoterol 2Y02
dobutamine 2Y00-2Y01
isoproterenol 2Y03
salbutamol 2Y04
b2-adrenergic BI-167107 3P0G-3SN6
procaterol 3PDS
Adenosine A2A adenosine 2YDO
NECA 2YDV
UK-432097 3QAK
Structures are grouped on the basis of the efficacy of the ligands that
were cocrystalized: inverse agonists, antagonists, and agonists.
aEthyl 4-[(2S)-2-hydroxy-3-[(propan-2-yl)amino]propoxy]-3-methyl 1-
benzofuran 2-carboxylate.
b6-(2,6-dimethylpyridin-4-yl)-5-phenyl-1,2,4-triazin-3-amine.
c4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol.dark-adapted rhodopsin (Palczewski et al., 2000), which allowed
an accurate determination of amino acid side chain conforma-
tions, as well as the extracellular and intracellular loops and
the N- and C-terminal domains.
Collectively, the information gained from these models pro-
vided structural explanations for the role of specific sequence
features that are highly conserved among the large class A
subgroup of GPCRs that include rhodopsin, the monoamine
receptors, and numerous peptide and lipid receptors. (This
review will focus on class A receptors for which the principal
structural advances have been realized.) It was previously shown
for these receptors that a sequence element, termed the DRY (or
E/DRY) motif, played a role in controlling receptor activity. The
structural models revealed the presence of a polar interaction
between an arginine located at the bottom of TMIII and a gluta-
mate on TMVI, providing a structural explanation for the role
of this conserved features. The so-called ‘‘ionic lock’’ formed
between TMIII and TMVI was proposed to stabilize the inactive
state of the receptor (Figures 1 and 2). Consistent with this
notion, biophysical studies on rhodopsin (Altenbach et al.,
2008) and the b2-adrenergic receptor (b2AR) (Yao et al., 2006)showed that disruption of the interaction leads to TMVI move-
ment away from the TM bundle, creating a crevice to cradle
the heterotrimeric G protein. The similar findings for rhodopsinCell 151, September 28, 2012 ª2012 Elsevier Inc. 15
Figure 2. Configurations of the ‘‘E/DRY,’’ ‘‘Ionic Lock,’’ and ‘‘NPXXY’’
Motifs in Rhodopsin, Opsin, and Antagonist-Bound b2AR
Bottom views of rhodopsin (PDB ID:1GZM), opsin (PDB ID:3DQB), and b2-
adrenergic receptor (b2AR) (PDB ID:2RH1). TM domains are shown as ribbons,
whereas the important residues of the E/DRY, ionic lock, and NPXXYmotifs are
shown as stick renderings and are indicated by solid lines. The structure of
rhodopsin represents the inactive conformation of the receptor, whereas the
opsin structure is in an active-like conformation. The dotted circles overlaid on
the opsin structure indicate the positions of TMV, TMVI, and TMVII in the inactive
rhodopsin, and the orange dotted arrows illustrate the TM movements from
inactive toactivestates.The ionic interaction (ionic lock), representedbyadotted
line between the R of the E/DRY motif and a negatively charged glutamate (E)
residue in TMVI, is believed to stabilize the receptor in an inactive state. In the
opsin structure, anactive-like retinal-free state of rhodopsin, the disruptionof the
ionic lock allows TMVI tomove away from the receptor bundle anddown toward
the cytoplasmic interface with the heterotrimeric G protein. Simultaneously, the
tyrosine (Y) residue of the NPXXYmotif moves inside the bundle, blocking TMVI
in an open conformation. The ionic lock is, however, not found in most of the
antagonist-boundGPCRstructures obtained to date. This is exemplifiedhere by
the structure of the b2AR bound to the antagonist (inverse agonist) carazolol,
where the ionic lock is not formed, indicating that an alternative configuration is
involved in the stabilization of the closed state of the receptor.
16 Cell 151, September 28, 2012 ª2012 Elsevier Inc.and the b2AR popularized the notion that ligand binding would
lead to full receptor activation through a common conserved
mechanism. Yet, the lack of a 3D structure for an activated
receptor prevented a complete understanding of the molecular
processes linking ligand binding to receptor activation.
Methodological Breakthroughs
Seven years following the crystallization of mammalian rhodop-
sin, the structure of human b2AR in complex with the b-adren-
ergic antagonist carazolol was solved (Cherezov et al., 2007;
Rasmussen et al., 2007; Rosenbaum et al., 2007). Attaining
this goal requiredmajor methodological hurdles to be overcome.
First, large quantities of homogeneous receptor were needed—
a task that was complicated by the lower expression of GPCRs
binding diffusible ligands compared to rhodopsin. This problem
was circumvented by overexpressing the receptors in special-
ized systems while the sources of microheterogeneity such as
putative phosphorylation and glycosylation sites were elimi-
nated by mutagenesis. Second, the stability of these intrinsically
dynamic GPCRs needed to be increased to avoid aggregation
and to facilitate crystal lattice packing. Because the third intra-
cellular loop (ICL3) (Figure 1) is a particularly flexible domain,
different strategies were designed to stabilize this part of the
receptor. In a few cases (Rasmussen et al., 2007; Bokoch
et al., 2010), an antibody Fab fragment recognizing ICL3 was
bound to the receptor. In many other cases, ICL3 was deleted
and replaced by well-folded soluble proteins such as T4 lyso-
zyme (Chien et al., 2010; Jaakola et al., 2008; Rosenbaum
et al., 2007; Wu et al., 2010, 2012) or the apocytochrome
b564RIL (Thompson et al., 2012). Thermo-stabilizing mutations
have also been used to obtain receptor preparations compatible
with crystal formation (Warne et al., 2008; Dore´ et al., 2011;
Lebon et al., 2011). The residues selected to stabilize the re-
ceptors were first identified empirically by testing a very large
number of mutations and selecting those with the greatest
impact on stability. In most cases, between four and eight muta-
tions were needed to obtain the required stability.
As for many membrane proteins, GPCR crystallization re-
quires conditions adapted to the hydrophobic nature of the
protein. In an effort to satisfy this requirement, several methods,
including detergent-based micelles, bicelles (Faham and Bowie,
2002), and in particular, lipidic cubic phase systems (Landau
and Rosenbusch, 1996; Pebay-Peyroula et al., 1997), were
developed and used successfully. Despite optimized conditions,
GPCR crystals tend to be small. The development of microfocus
X-ray synchrotron technologies that deliver a microscale beam
to a crystal (Riekel et al., 2005) greatly contributed to generating
the high-resolution structures.
An Explosion of Structures
The wealth of structural information emerging over the last 5
years (Table 1) forms the basis of a real revolution in GPCR
research. The structural and functional models that arise from
them have changed our views on GPCR agonist and antagonist
binding modes and on the activation processes.
Ligand Recognition
As expected, the overall folding of the TM domain is highly
conserved among all structures and was well predicted by the
Figure 3. Distinct Binding Modes for GPCR Ligands
Top and side views of the human b2AR (PDB ID:2RH1), S1P1R (PDB ID:3V2Y), human A2AAR (PDB ID:3EML), and human CXCR4 (PDB ID:3ODU) shown as
ribbons with their respective cocrystallized ligand shown in gray spheres. The black solid lines indicate the position of the ECL and N terminus. The four receptors
display different relative ligand orientations in the binding pocket and changes in the extracellular domain fold, revealing a great diversity in ligand binding.
Interestingly, b2AR, A2AAR, and CXCR4 have freely accessible binding pockets that are the consequence of a compact extracellular domain that does not
obstruct the entry of ligands from the extracellular side. In contrast, the N terminus and ECL2 of S1P1 extend on the top of the receptor, covering the opening of the
receptor, thereby precluding any ligand exchange with the extracellular compartment. Therefore, an alternative path for ligand entry has been proposed between
TMI and TMVII.structures of eukaryotic rhodopsin, showing only modest differ-
ences in the relative orientation of the TMs. However, more
striking differences are found in the extracellular loop domains
and especially in the second extracellular loop (ECL2) that clearly
displays receptor-specific folds (Figure 3). These domains act
as a vestibule directing the way ligands access the receptor-
binding pocket. For example, the ECL2 of many receptors,
including the b2AR (Figure 3, top left), form a compact helical
shape adjacent to the TM bundle that, along with the small
ECL1 and ECL3, allows soluble ligands to diffuse easily from
the extracellular compartment toward the binding site inside of
the receptor bundle (Rosenbaum et al., 2007). In contrast, as
was observed for rhodopsin (albeit through a different fold), the
ECL2 of the S1P1 receptor, along with ECL1 and the N-terminal
helices, seals off the ligand-binding pocket (Figure 3, top right),
blocking access from the extracellular milieu (Hanson et al.,
2012). The structure suggests that the lipid agonist S1P ac-
cesses the receptor by a TMI-TMVII intrabundle opening near
the plasma membrane. Interestingly, the extent of opening of
each receptor’s ‘‘mouth’’ determined by the relative position of
ECL2 varies considerably between receptors, revealing an unex-pected diversity of ligand entry mechanisms. In addition to their
role in channeling the ligands toward the binding pocket, these
extracellular domains have been suggested to contribute to
both binding kinetics and selectivity (Dror et al., 2011).
As the structures have revealed diversity in how ligands
access the receptor, so too have they illuminated specific
aspects of ligand recognition. Classical views of how ligands
might bind were sculpted by generalization from the retinal/
rhodopsin structure (Palczewski et al., 2000) and early aminergic
receptor modeling (Flower, 1999), in which ligands were pre-
dicted to lie parallel to the plane of the membrane deep in the
TM bundle (Figure 3, top left). The new structures broaden our
understanding on this front. For instance, both agonists and
antagonists (Figure 3, bottom left) of A2A adenosine receptor
(A2AAR) bind in an extended conformation perpendicular to the
plane of the membrane where they are stabilized by extensive
contacts with ECL2 and ECL3 (Dore´ et al., 2011; Jaakola et al.,
2008; Xu et al., 2011). For CXCR4 (Figure 3, bottom right), the
antagonist IT1t unexpectedly binds the receptor at its surface
between TMVII, TMI, TMII, and ECL2 (Wu et al., 2010). In
contrast, b2AR shows the ‘‘canonical’’ deep TMVI-TMIII-TMVCell 151, September 28, 2012 ª2012 Elsevier Inc. 17
aminergic binding pocket (Figure 3, top left), as do the musca-
rinic M2 and M3 receptors (M2R and M3R), although ligands
for these latter receptors are protected by a three-dimensional
aromatic cage (Haga et al., 2012; Kruse et al., 2012). Similarly,
the S1P1R antagonist ML056 (Figure 3, top right) binds a highly
hydrophobic and polyaromatic region deep in the receptor,
but the ligand also projects phosphate and amine groups verti-
cally toward charged and polar residues packed between the
N-termini, ECL2, TMVII, TMII, and TMIII (Hanson et al., 2012). It
should also be noted that the size of the binding sites greatly
diverges among receptors, ranging from the small compact
binding pocket of the eticlopride-bound dopamine receptor
(Chien et al., 2010) to the large surface of the CXCR4-binding
pocket required to accommodate the fold of the bound CVX15
peptide (Wu et al., 2010). These results clearly indicate that
each receptor has a binding site that is specifically adapted to
the nature of its ligands. These data open new perspective in
the rational design of ligands that are better adapted to unique
binding pockets.
The rich diversity of the ligand-receptor complexes indicates
that ligand selectivity cannot be simply explained by different
amino acids within shared ligand binding pockets, but that it
also depends on the overall receptor architecture involving resi-
dues in different domains of the receptor. A good example is
provided by the b1AR and b2AR structures that revealed a very
high degree of identity between the residues found in the
‘‘canonical’’ aminergic binding pocket (Warne et al., 2008) de-
spite the existence of clear receptor subtype selectivity. Such
selectivity has been proposed to result in part from ligand-
induced conformational changes (Wacker et al., 2010) and to
involve interactions with ECL residues (Audet and Bouvier,
2008; Rosenbaum et al., 2007; Warne et al., 2008). A role for
residues close to the extracellular domains in determining the
ligand binding selectivity was also observed for the recently
solved structure of the delta-opioid receptor (Granier et al.,
2012). The crystal structure of the nociceptive/orphanin FQ
receptor (NOP) also shows that most of the residues that are
different between NOP and the other members of the opioid
receptor family are not in direct contact with the ligand in the
binding pocket but rather are involved in large pocket reshaping
and water coordination.
The diversity in binding modes also has important implications
for the activation process of the receptors, as it suggests that no
unique activation trigger can be invoked for all GPCRs. Instead,
the engagement of distinct regions of the receptors by their
ligands predicts that different allosteric transitions will be needed
to reach a common active state.
Activation and Allosteric Transition
GPCR ligands can be divided into two general classes: agonists
that promote and antagonists that block receptor activation.
Antagonists can be subdivided into inverse agonists, which
inhibit the spontaneous (agonist-independent) activity of the
receptors, and neutral antagonists that are devoid of intrinsic
activity and block the action of both agonists and inverse
agonists. Out of the 47 ligand-bound GPCR structures, 36
were cocrystallized with antagonists (including 16 with inverse
agonists), whereas 11 were cocrystalized with agonists (Table
1). Somewhat surprisingly, few differences could be seen18 Cell 151, September 28, 2012 ª2012 Elsevier Inc.between the agonist and antagonist-bound forms, yielding
relatively little information on the dynamics of receptor activation
and on the conformational changes underlying ligand-promoted
activation. Exemplifying this point is the observation that struc-
tures of the G-protein-free b2AR cocrystalized with full or partial
agonists are very similar to those with antagonist or inverse
agonist and mostly display the characteristics of an inactive
conformation (Figure 4). These limited changes are consistent
with a model for full GPCR activation that requires both ligand
binding and G protein engagement.
Fortunately, three structures provided significant insights in
the activation mechanism. The first one is a ligand-free form of
opsin that is cocrystalized with the C terminus of the a-subunit
of the heterotrimeric visual G protein, transducin (Scheerer
et al., 2008). This structure confirmed earlier predictions about
TMVI movement from site-directed mutagenesis and biophys-
ical studies. When compared with dark-adapted rhodopsin, a
large outward movement of TMVI and disruption of the ionic
lock between TMIII and TMVI were observed (Figure 2). In addi-
tion, this structure provided new insight into conformational rear-
rangements that facilitate G protein binding. In the active opsin,
TMVII bends inward, allowing the repositioning of the tyrosine
from the conserved NPXXY motif, which prevents the reverse
movement of TMVI, thus stabilizing the open state that forms
a cradle for transducin (Figure 2). In parallel, the arginine of the
DRYmotif juts into the bundle of the receptor, providing an inter-
acting floor for transducin’s C terminus. TMV is also repacked
against TMVI, offering an additional interacting surface for the
G protein.
The two additional structures that provided insights into the
activation process are the agonist-bound b2AR stabilized in the
active conformation by a nanobody mimicking the G protein
(Rasmussen et al., 2011a) and the agonist-bound b2AR cocrys-
tallizedwith heterotrimeric stimulatory G protein (Gasb1g2) (Ras-
mussen et al., 2011b). The C terminus of Gas lies deep in a
pocket created by the outward movement of TMVI, and most
of the Ga interaction sites are found on TMIII, TMV, TMVI, and
ICL2 of the receptor. As shown in Figure 4B, comparison of the
agonist-bound G-protein-coupled b2AR structure with that of
the G-protein-free receptor bound to the inverse agonist carazo-
lol showed significant conformational rearrangements that are
similar to those observed for the active opsin. The noticeable
differences were a larger outward movement and bending of
TMVI and the formation of a bulge in TMV that positions a serine
residue (S207) closer to the agonist, providing a structural expla-
nation for the well-known increase in agonist affinity promoted
by G protein coupling. Together, these changes represent key
determinants of the allosteric transition toward a receptor state
activating the G protein.
Nucleotide Exchange
The three structures that incorporate fragments of G proteins
or G-protein-mimetics also provide insight into how GPCRs
facilitate nucleotide exchange and, hence, initiate signaling
cascades. The receptor-coupled structures of the G proteins
show that the helical domain of Ga undergoes a major rigid-
body rotation of almost 130 upon receptor engagement (Fig-
ure 4B) that was previously predicted by modeling (Cherfils
and Chabre, 2003) and biophysical studies (Gale´s et al., 2006).
Figure 4. Fully Activated Conformations Require the Presence of Both Agonist and G Protein
(A) Schematic illustration of ligand binding and G protein engagement leading to a fully activated conformation of a receptor.
(B) Side and bottom views of the b2AR. Top left, bound to the antagonist (inverse agonist) carazolol (PDB ID: 2RH1); bottom left, covalently bound to the agonist
procaterol (PDB ID: 3PDS); and top right, bound to the agonist BI-167107 in the presence of Gasb1g2 (PDB ID: 3SN6). Black dotted lines and circles illustrate the
position of TMVI and TMVII in the inverse agonist-bound (inactive state) structure, whereas yellow dotted lines illustrate their position in the Gs and agonist-bound
structure (active state). The TM movements from the inactive to active states are indicated by yellow and orange arrows. It should be noted that the large
movements of the receptor leading to its open and active conformation were observed only in the presence of both agonist and G protein (top right). The structure
obtained in the presence of the agonist alone (bottom left) was similar to the inactive structure obtained in the presence of inverse agonist (top left). To illustrate the
conformational rearrangement of the G protein during the activation process, the helical domain structure of the nucleotide (GTPƴS)-bound heterotrimeric Gs
(PDB ID: 1AZS) was overlaid on the structure of the receptor-bound Gas (bottom right). The blue dotted arrow indicates the large rigid-body movement of the
helical domain of Gas that suggests a possible structural basis for the nucleotide exchange promoted by receptor activation.
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The G-protein-bound nucleotide is pinched between the
GTPase and the helical domain in the inactive heterotrimeric
G protein structures (Wall et al., 1995), and this movement
provides a possible structural basis for the nucleotide exchange
promoted by receptor activation (Rasmussen et al., 2011b;
Chung et al., 2011). These receptor conformational rearrange-
ments underlying G protein activation may be shared by many
GPCRs.
Ligand-Promoted Activation
Besides b2AR and b1AR, the A2AAR is the only other GPCR
that has been crystallized in the presence of both agonists and
antagonists. Focusing on the chemical differences between
agonists and antagonists reveals molecular interactions that
could explain early events in activation. For the bARs, the extent
of binding of the hydroxyl groups of their catecholamine ligands
may be essential to promote the reorganization of TMV, TMVI,
and TMVII, yielding the active conformation (Warne et al.,
2011). In the case of the A2AAR, the ribose group of agonists
binds directly to residues in TMVII, leading to a reconfiguration
of the NPXXY motif (Lebon et al., 2011; Xu et al., 2011), which
suggests an important role for TMVII in the transition of A2AAR
toward its active state. Yet, the available agonist-bound struc-
tures of A2AAR most likely do not represent the fully activated
state of the receptor because the TMVI only undergoes amodest
outward movement that is insufficient to allow heterotrimeric G
protein engagement. It is tempting to speculate that this move-
ment could be facilitated by the presence of a G protein. This
is consistent with the fact that, for the b2AR, major structural
changes occur only in the presence of the G protein or the G-
protein-mimicking nanobody (Rasmussen et al., 2011b). Thus,
it can be hypothesized that conformational changes leading to
receptor activation are driven or at least stabilized in part by G
protein coupling and not only by ligand binding.
The agonist-bound structures of bAR and A2AAR suggest that,
although the global molecular rearrangement leading to an
active state is very similar among class A GPCRs (Figure 4B),
the specific ligand-receptor contacts triggering the activation
can differ. However, it is noteworthy that, in both cases, the
receptor domains involved in the binding of the agonists are
implicated in the activation transition, suggesting that agonists
most likely act by stabilizing at least one of the distinct conforma-
tional rearrangements involved in the propagation of the activa-
tion transition. In addition, the observation that the A2AAR can
adopt a structure with an activated-like TMVII conformation
while having a closed TMVI is a clear illustration of the conforma-
tional plasticity of GPCRs and suggests that the various features
of an activated state can be differentially controlled. This may
help explain how some ligands can selectively activate only a
subset of the effectors that can be engaged by a given receptor,
which is a concept known as functional selectivity or ligand-
biased signaling (Galandrin et al., 2007).
Receptor Activation circa 2012
The available crystal structures lead to the reassessment of
some hypotheses that were formulated a decade ago about
the receptor activation process based on the structure of dark-
adapted rhodopsin. First, the ionic lock between the Arg of the
DRY motif and a negatively charged residue on TMVI that was20 Cell 151, September 28, 2012 ª2012 Elsevier Inc.proposed as a major determinant of the inactive receptor state
as described above (Figure 2) are not present in all antagonist-
bound structures. As an example, the ionic lock is not formed
in the structure of the b2AR cocrystalized with the antagonist car-
azolol (Figure 2). In fact, only three receptor structures (A2AAR,
b1AR, and D3R) show this ionic contact. Even for those three
receptors, only a subset of the antagonist-bound structures ob-
tained showed a closed ionic lock (Dore´ et al., 2011; Moukha-
metzianov et al., 2011), suggesting that this polar interaction
may oscillate between open and closed in the basal state, thus
explaining the constitutive (agonist-independent) activity of the
receptor. Alternative stabilization strategies of the inactive state,
such as nonionic interactions between the DRY motif and TMVI,
are emerging (Granier et al., 2012; Hanson et al., 2012; Manglik
et al., 2012; Thompson et al., 2012; Wu et al., 2010, 2012). Addi-
tional structures will be required to develop a more definitive
view of how inactive receptor conformations are stabilized in
the presence or absence of inverse agonists or neutral antago-
nists.
Another prediction made from the early rhodopsin structures
was that the movement of TMVI is triggered by the ligand-
induced repacking of a few residues that acts as a ‘‘toggle
switch’’ in the vicinity of a conserved TMVI proline kink through
rotation of their side chains (rotamerization). Yet, with the excep-
tion of the muscarinic receptors (Haga et al., 2012; Kruse et al.,
2012), no rotameric transition of these residues was observed,
even in the cases of the opsin/transducin, b2AR/nanobody,
and b2AR/heterotrimeric G protein complexes that likely repre-
sent fully active structures. Thus, although they could still
represent an important structural element supporting receptor
activation, their rotamerization may not be required for receptor
activation.
Oligomerization in Signaling
A large body of biochemical and biophysical work supports the
notion that GPCRs can form physiologically relevant oligomers
(Angers et al., 2002). Although dimers and larger oligomers
were detected in some of the early rhodopsin crystals, they
were largely attributed to crystallization artifacts. The first b2AR
structure was also solved as a dimer (Rosenbaum et al., 2007),
but the interactions mainly occurred through associated choles-
terol and palmitate molecules with very little involvement of
protein-protein contacts, which again raised questions about
the physiological relevance of oligomerization. Dimers found
within three of the recent structures (Figure 5) have renewed
interest in dimerization in GPCR function. The CXCR4 structures
revealed a consistent homodimer interface of 850Ǻ2 of buried
surface, including TMV and TMVI (Wu et al., 2010). The m-opioid
receptor (mOR) structure presents two dimer interfaces: a small
one involving a TMI-TMII-helix 8 interaction with 615 A˚2 of buried
surface and a larger one between TMV and TMVI covering
1492 A˚2 of buried surface (Manglik et al., 2012). The presence
of two distinct interfaces on opposite sides of the receptor offers
a plausible structural basis for the formation of higher-order olig-
omers. Of notice, some of the residues involved in binding the
opioid ligands are in direct contact with the amino acids present
at the TMV-TMVI dimerization interface, providing a mechanism
for the allosteric regulation of the dimerization process. Also, the
Figure 5. Possible Dimerization Interfaces Revealed by GPCR
Crystal Structures
(A) Side views of CXCR4 (PDB ID: 3ODU), mOR (PDB ID: 4DKL), and kOR (PDB
ID: 4DJH) dimers. The position of the TM domains at the dimerization interface
is indicated by solid black lines. Both TMI-TMII-helix 8 (H8) and TMV-TMVI
interfaces are found in the mOR, suggesting a plausible structural basis for the
formation of higher-order oligomers.
(B) Schematic illustration of a possible mechanism for interprotomer allosteric
regulation of receptor activity involving R165 of the DRY motif and a threonine
residue (T279) that lies at the TMV-TMVI interface of the mOR dimer. Interac-
tions between R165 and T279 are shown by a dotted line.observation that T279, which stabilizes the closed position of
TMVI in the inactive receptor state by interacting with R165 of
the DRY motif, is packed within the TMV-TMVI interface
offers a possible mechanism for interprotomer regulation of
receptor activity (Figure 5). However, the TM5-TM6 interface is
not present in the k-opioid receptor (kOR) dimer structure.
Indeed, only one interface (1100 A˚2 of buried surface), involving
the TMI, TMII, and helix 8, is visible in this structure (Wu et al.,
2012). The absence of the TMV-TMVI interface in the kOR struc-
ture is somewhat surprising given the high level of sequence
identity with the mOR in these TMs and may be due to the steric
hindrance from the two T4 lysozyme inserts included to aid crys-
tallization of kOR. Whether the dimerization interfaces revealed
by the recently solved structures correspond to the functionallyrelevant dimers will require additional studies involving site-
directed mutagenesis and biochemical and biophysical ap-
proaches, but the structures provide rational starting points for
this work.
Conclusion
The recent flurry of high-resolution GPCR structures represents
a true renaissance for GPCR research. Although much remains
to be done to fully understand the precise molecular mecha-
nisms controlling receptor activities, the achievements of the
last 5 years provide the foundation of what promises to be
very exciting times for structure-based molecular pharmacology
and drug discovery. An emerging theme stems from the
observation that GPCRs function as molecular hubs that can
engage several distinct G proteins, as well as G-protein-inde-
pendent signaling pathways, and that different ligands pro-
mote the engagement of distinct subsets of effectors (Galandrin
et al., 2007). At the molecular level, such ligand-biased signaling
is believed to result from the stabilization of different active
conformations of the receptors (Bokoch et al., 2010). A future
challenge for structural biology will therefore be to provide
high-resolution images of these different receptor states with
the goal of designing ligands—and ultimately drugs—to selec-
tively control specific functions. As discussed above, the struc-
tures obtained when cocrystalizing receptors with ligands
displaying distinct efficacy profiles revealed very similar struc-
tures, indicating that solving the structures of receptor-ligand
complexes may not be sufficient to fully explore the confor-
mational plasticity of GPCRs underlying their rich biology. The
observation that cocrystallization with a G protein or a mimic
was needed to reveal a fully active conformation suggests
that solving structures of GPCRs in complex with specific effec-
tors such as different G proteins, b-arrestins, or GPCR kinases
will be needed to unravel the true diversity of receptor confor-
mations.
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